Our scientific roadmap : FlashRNA® in the future
All technologies can always be improved. Our team is consistently working to enhance the capabilities of FlashRNA®. We want to make it more powerful, cheaper to produce, together with a more reliable production process.
1.
FlashRNA®– Precision for specific cell targeting
Our goal is to empower FlashRNA® with the ability to specifically target cell types in vivo.
By leveraging appropriate surface receptors, this next-generation RNA delivery platform will be capable of autonomously identifying and delivering its genetic payload to the right cells.
2.
Stable packaging cell lines
Our objective is to significantly reduce production costs and streamline the bioproduction process.
We are working on the generation of a new stable manufacturing cell line engineered with a specific genetic code, dedicated to FlashRNA® manufacturing.
3.
Thermostability
A key objective of this effort is to ensure that FlashRNA® batches can be stably stored for extended periods at temperatures compatible with vaccine use — a critical step toward making the technology viable for real-world vaccination programs.
We are conducting multi-month studies to optimize FlashRNA® for vaccine applications.
4.
Suspension culture
In a field that demands agility and scalability, we are committed to making FlashRNA® compatible with suspension culture, enabling seamless adaptation to our clients’ production needs.
At RNAlead, we don’t see adherent and suspension systems as competitors, but as complementary tools. Our goal is to match each process to each project, ensuring the most efficient and tailored solution for every therapeutic challenge.
The FlashRNA® used to treat secondary lymphedema
Our FlashRNA® technology is involved in a Phase I / II clinical trial with the aim to restore the normal function of the lymphatic system in the limb of patients who developed lymphedema after breast cancer treatment. FlashRNA® was chosen as the ideal tool because it can carry two different factors and express them temporarily in patients without any risk of altering their genome.
Contact us
Do you have a project in mind? We’d love to hear from you!
